{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T10:25:54Z","timestamp":1792664754273,"version":"4.5.0"},"reference-count":17,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Ophthalmol"],"published-print":{"date-parts":[[2018,11,1]]},"DOI":"10.1001\/jamaophthalmol.2018.3488","type":"journal-article","created":{"date-parts":[[2018,10,25]],"date-time":"2018-10-25T04:55:51Z","timestamp":1540443351000},"page":"1236","source":"Crossref","is-referenced-by-count":111,"title":["Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma"],"prefix":"10.1001","volume":"136","author":[{"given":"Oded","family":"Sagiv","sequence":"first","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudip D.","family":"Thakar","sequence":"additional","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kandl","sequence":"additional","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Ford","sequence":"additional","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew C.","family":"Sniegowski","sequence":"additional","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Jen","family":"Hwu","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Esmaeli","sequence":"additional","affiliation":[{"name":"Orbital Oncology and Ophthalmic Plastic Surgery, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"eoi180069r1","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1586\/17469899.2014.921119","article-title":"Management of conjunctival malignant melanoma: a review and update.","volume":"9","author":"Wong","year":"2014","journal-title":"Expert Rev Ophthalmol"},{"key":"eoi180069r2","first-page":"64","article-title":"Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis).","volume":"110","author":"Esmaeli","year":"2012","journal-title":"Trans Am Ophthalmol Soc"},{"key":"eoi180069r3","first-page":"471","article-title":"Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.","volume":"98","author":"Shields","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"17","key":"eoi180069r7","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1200\/JCO.2014.56.2736","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma.","volume":"33","author":"Schadendorf","year":"2015","journal-title":"J Clin Oncol"},{"issue":"14","key":"eoi180069r8","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1158\/1078-0432.CCR-16-0714","article-title":"FDA approval of nivolumab for the first-line treatment of patients with BRAFV600 wild-type unresectable or metastatic melanoma.","volume":"23","author":"Beaver","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"14","key":"eoi180069r9","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1158\/1078-0432.CCR-16-0712","article-title":"US FDA approval summary: nivolumab for treatment of unresectable or metastatic melanoma following progression on ipilimumab.","volume":"23","author":"Hazarika","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"20","key":"eoi180069r10","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"4","key":"eoi180069r11","doi-asserted-by":"publisher","first-page":"e82","DOI":"10.1097\/IOP.0000000000000790","article-title":"Immune checkpoint inhibitors for treatment of metastatic melanoma of the orbit and ocular adnexa.","volume":"33","author":"Ford","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"12","key":"eoi180069r12","doi-asserted-by":"publisher","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"33","key":"eoi180069r13","doi-asserted-by":"crossref","first-page":"54722","DOI":"10.18632\/oncotarget.18039","article-title":"PD-L1\/PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma.","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"eoi180069r14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for recurrent conjunctival melanoma.","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"eoi180069r15","first-page":"4623964","article-title":"Systemic treatment of metastatic conjunctival melanoma.","volume":"2017","author":"Pinto Torres","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"eoi180069r16","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.ejca.2017.01.035","article-title":"Cancer immunotherapy: opportunities and challenges in the rapidly evolving clinical landscape.","volume":"81","author":"Emens","year":"2017","journal-title":"Eur J Cancer"},{"issue":"6","key":"eoi180069r17","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1097\/IAE.0000000000002181","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects.","volume":"38","author":"Dalvin","year":"2018","journal-title":"Retina"},{"key":"eoi180069r4","unstructured":"US Food and Drud Administration. YERVOY [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125377s074lbl.pdf. Accessed July 7, 2018."},{"key":"eoi180069r5","unstructured":"US Food and Drug Administration. KEYTRUDA [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125514s015lbl.pdf. Accessed July 7, 2018."},{"key":"eoi180069r6","unstructured":"US Food and Drug Administration. OPDIVO [package insert]. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125554s024lbl.pdf. Accessed July 7, 2018."}],"container-title":["JAMA Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaophthalmology\/fullarticle\/2697401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,8]],"date-time":"2018-11-08T16:03:59Z","timestamp":1541693039000},"score":1,"resource":{"primary":{"URL":"http:\/\/archopht.jamanetwork.com\/article.aspx?doi=10.1001\/jamaophthalmol.2018.3488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":17,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaophthalmol.2018.3488","relation":{},"ISSN":["2168-6165"],"issn-type":[{"value":"2168-6165","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}